Dokumente
Europa English European Agencies EMA
11.04.2025
News
European Medicines Agency 

Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 8-9 April 2025

The Committee adopted by consensus a positive opinion for a marketing authorisation from Intervet International B.V. for Nobilis Multriva IBm+ND, for the active immunisation of chickens for reduction of respiratory signs and egg drop caused by infectious bronchitis virus (IBV) strains Massachusetts (GI-1 genotype) and 4/91-793B (GI-13 genotype) and reduction of mortality and clinical signs caused by Newcastle disease virus (NDV). The Committee adopted by consensus a positive opinion for a ma...
The Committee adopted by consensus a positive opinion for a marketing authorisation from Intervet International B.V. for Nobilis Multriva IBm+ND, for the active immunisation of chickens for reduction of respiratory signs and egg drop caused by infectious bronchitis virus (IBV) strains Massachusetts (GI-1 genotype) and 4/91-793B (GI-13 genotype) and reduction of mortality and clinical signs caused by Newcastle disease virus (NDV). The Committee adopted by consensus a positive opinion for a marketing authorisation from Intervet International B.V. for Nobilis Multriva Gm+REOm for the active immunisation of chickens for passive immunisation of the progeny of the vaccinated chickens to reduce mortality and clinical signs of disease caused by very virulent (CS89) and classical (STC) strains of infectious bursal disease virus (IBDV), and to reduce viraemia and clinical signs of disease caused by avian reovirus (ARV) genotypes 1 and 4. The Committee adopted by consensus a positive opinion for a marketing authorisation from CP-Pharma Handelsgesellschaft mbH for Emevet (maropitant), for the prevention of nausea induced by chemotherapy and the prevention of vomiting induced by motion sickness in dogs. The Committee adopted by consensus positive opinions for variations requiring assessment concerning quality-related changes for: The Committee adopted by consensus positive opinions for variations requiring assessment to align the product information with version 9/9.1 of the QRD...

Angaben ohne Gewähr. Stand: 11.04.2025